S&P 5007,785.76▼0.2% Nasdaq26,729.16▼0.3% Dow53,732.41▼0.2% Russell 2K3,068.42▲0.5% 10-Yr4.70%+6bp VIX14.25−0.38 WTI$82.40▲1.4% Gold$4,432.00▲1.6% EUR/USD1.157▲0.4% BTC$62,958▼0.7% Nikkei68,309▲1.2%
At close · Fri, Aug 14, 2026
Daily Market Updates.

Earnings

HomeEarningsResultsHims & Hers shares fall after margin drop as it raises…

Hims & Hers shares fall after margin drop as it raises GLP-1 sales outlook

The telehealth company posted a $86.3 million net loss, reversing from profit a year earlier, even as revenue rose 38% to $753.2 million and full-year revenue guidance climbed to $3.1 billion to $3.3 billion.

Hims & Hers Health, Inc. (NYSE: HIMS) shares fell more than 6% in extended trading on August 10 after the telehealth company reported rapid revenue growth paired with sharply weaker profitability.

Revenue increased 38% year over year to $753.2 million, subscribers rose 19% to 2.89 million, and Monthly Revenue per Average Subscriber climbed 21% to $92. The company also raised its full-year revenue outlook to $3.1 billion to $3.3 billion, from a previous range of $2.8 billion to $3.0 billion.

The earnings picture, however, deteriorated. Hims & Hers reported an $86.3 million net loss, or 37 cents per share, versus a $42.5 million profit a year earlier, while gross margin fell to 64% from 76%, according to the results.

The quarter focused on the company’s GLP-1 product transition, after it expanded its branded weight-loss assortment through an agreement with Novo Nordisk in March and stopped broadly advertising compounded GLP-1 drugs. Management said the branded shift supported renewed domestic growth, with U.S. revenue up 16% year over year to $621.8 million, and subscriber net adds continuing through the transition including contributions from Eucalyptus, which joined the company in June.

More like this

Sources

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.